Daniel Auclair, President at Hematocure, LLC shared a post on X:
“Impressive early data presented for JNJ’4496 dual CD19/CD20 CART in R/R LBCL at EHA2025. 100% ORR and 80% CR at RP2D. No Gr. 3/4 CRS to date, no prophylactic therapy for ICANS or CRS.”
More posts featuring EHA 2025 on OncoDaily.
